Rankings / Muscle & Strength

Muscle & Strength

TRT, SARMs, anabolic steroids, peptide GH-secretagogues, and the off-label performance corner. Large effect sizes, meaningful risk, and serious legal exposure.

Compounds ranked
44
Top-ranked
# Compound Class Ev Bn Sf Grade · Score
1 Resistance training
Movement
Protocol 10 8 9 S 9.3
2 Beta-alanine
Carnosine precursor
Supplement 8 6.5 9 A+ 8.2
3 Blood flow restriction (BFR) training
Movement
Protocol 8 8 7 A- 7.6
4 Testosterone (TRT / supraphysiological)
Endogenous androgen (AR agonist)
Anabolic 8 8 5 B 6.8
5 Anavar (oxandrolone)
Oral anabolic steroid
Anabolic 8 6.5 5 B 6.6
6 Sodium bicarbonate
Extracellular buffer
Supplement 8 6.5 5 B 6.6
7 Tesamorelin
Stabilized GHRH analog
Anabolic 8 5 3.5 B- High-risk profile 5.8
8 Deca-Durabolin (nandrolone decanoate)
Injectable 19-nor steroid
Anabolic 8 8 2 C+ High-risk profile 5.6
9 Dianabol (methandrostenolone / methandienone)
Oral anabolic steroid (C17-aa)
Anabolic 8 8 2 C+ High-risk profile 5.6
10 EPO / erythropoiesis-stimulating agents (ESAs)
Erythropoietin receptor agonist
Prescription 8 8 2 C+ High-risk profile 5.6
11 Nandrolone (phenylpropionate / other esters)
Injectable 19-nor steroid
Anabolic 8 8 2 C+ High-risk profile 5.6
12 Other WADA-listed anabolic androgenic steroids (AAS long tail)
Anabolic androgenic steroids / prohormones
Anabolic 8 8 2 C+ High-risk profile 5.6
13 Sermorelin
GHRH(1-29) analog
Anabolic 4.5 5 7 C+ 5.6
14 Ostarine (MK-2866 / enobosarm)
SARM
Anabolic 6 5 5 C+ 5.5
15 Primobolan (methenolone)
Injectable/oral anabolic
Anabolic 6 5 5 C+ 5.5
16 Winstrol (stanozolol)
Oral/injectable anabolic steroid
Anabolic 8 6.5 2 C+ High-risk profile 5.4
17 Boldenone (Equipoise)
Injectable veterinary anabolic
Anabolic 6 8 3.5 C+ High-risk profile 5.3
18 Anadrol (oxymetholone)
Oral anabolic steroid
Anabolic 8 10 0 C High-risk profile 5.1
19 Trenbolone
Injectable 19-nor steroid (~5x androgen activity)
Anabolic 8 10 0 C High-risk profile 5.1
20 Masteron (drostanolone)
Injectable DHT-derivative
Anabolic 6 6.5 3.5 C High-risk profile 5.1
21 HIF stabilizers / prolyl-hydroxylase inhibitors (roxadustat / daprodustat / vadadustat)
HIF activating agent
Prescription 6 5 3.5 C High-risk profile 4.9
22 MK-677 (ibutamoren)
Oral ghrelin receptor agonist
Anabolic 6 5 3.5 C High-risk profile 4.9
23 Myostatin / activin-pathway inhibitors (non-bimagrumab)
Myostatin/activin blockade
Anabolic 6 5 3.5 C High-risk profile 4.9
24 Ipamorelin
Selective ghrelin receptor agonist
Anabolic 3 5 7 C 4.9
25 Ligandrol (LGD-4033)
SARM
Anabolic 4.5 5 5 C 4.8
26 Artificial oxygen carriers / blood doping methods
Oxygen delivery manipulation
Supplement 6 8 2 C High-risk profile 4.7
27 Cardarine (GW501516)
PPAR-delta agonist (not a SARM)
Anabolic 6 10 0 C- High-risk profile 4.2
28 HGH (recombinant human growth hormone)
Recombinant peptide hormone
Anabolic 4.5 5 3.5 C- High-risk profile 4.2
29 CJC-1295 (with/without DAC)
GHRH analog
Anabolic 3 5 5 C- 4.1
30 GHRP-2 / GHRP-6
Ghrelin receptor agonists (earlier generation)
Anabolic 3 5 5 C- 4.1
31 Mesterolone (Proviron)
Oral DHT-derivative androgen / TRT adjunct
Anabolic 3 3.5 5 D+ 3.9
32 Other GH secretagogues / GHRPs
GH secretagogue / ghrelin receptor agonist
Anabolic 3 3.5 5 D+ 3.9
33 RAD-140 (testolone)
SARM
Anabolic 3 6.5 3.5 D+ High-risk profile 3.7
34 Long-acting GH analogs and GH fragments
Growth hormone analog / fragment
Research chemical 3 3.5 3.5 D High-risk profile 3.3
35 ACP-105
SARM
Anabolic 2 5 4 D 3.3
36 LGD-3303
SARM
Anabolic 2 5 4 D 3.3
37 Ryanodine stabilizers / fast skeletal muscle troponin activators
Muscle contractility modulator
Supplement 2.5 5 3 D High-risk profile 3.1
38 IGF-1 LR3 (long R3 insulin-like growth factor-1)
Modified IGF-1 analog
Anabolic 3 5 2 D High-risk profile 2.9
39 Veterinary growth promoters (ractopamine / zilpaterol / zeranol)
Veterinary beta-agonist / estrogenic growth promoter
Prescription 3 5 2 D High-risk profile 2.9
40 Andarine (S-4)
SARM
Anabolic 2 5 3 D High-risk profile 2.9
41 S-23
SARM
Anabolic 2 5 3 D High-risk profile 2.9
42 YK-11
Myostatin inhibitor / SARM-like
Anabolic 2 5 3 D High-risk profile 2.9
43 Gene and cell doping (performance-enhancing)
Gene/cell doping method
Supplement 2 5 0 F High-risk profile 1.7
44 Growth-factor doping agents (FGF / HGF / PDGF / VEGF / MGF)
Growth factor / tissue-remodeling signal
Supplement 2 5 0 F High-risk profile 1.7

This category has one of the widest gaps between effect size and risk in the database. Resistance training and several supplements combine higher grades with comparatively favourable Safety scores in studied settings. Other compounds have large, well-documented muscle-building effects alongside serious health and legal consequences. The rankings keep those axes visible side by side.

Strong evidence and lower reported risk

Resistance training has the highest composite in this category. Creatine monohydrate is extensively studied, with reliable strength and lean-mass gains and generally favourable safety findings. Adequate protein and, to a lesser degree, beta-alanine and HMB also occupy the evidence-backed, lower-risk portion of the ranking.

Approved and nonmedical contexts

Testosterone replacement has efficacy evidence in hypogonadal men, and the TRAVERSE trial (2023) found no increase in major cardiac events versus placebo in a higher-risk hypogonadal population. Supraphysiological use has a different safety profile and is illegal without a prescription. SARMs such as ostarine produce anabolic effects alongside liver, cardiovascular, and hormone-suppression risks; they are not approved for human use and are banned in sport.

Large effect, large cost

Classic anabolic steroids such as trenbolone and oxymetholone produce large anabolic effects alongside substantial reported harms, reflected in very low Safety scores. GH-secretagogue peptides such as ipamorelin, CJC-1295, and MK-677 raise growth hormone and IGF-1, while human outcome evidence remains thin and much of the supply is gray-market. The safety context label makes those findings visible without replacing the Benefit axis.

Frequently asked

Which muscle interventions combine stronger evidence with favourable safety findings?

Resistance training and adequate protein have broad evidence, while creatine monohydrate is among the most-researched sports supplements and produces reliable strength and lean-mass gains with generally favourable tolerability in studied populations.

What safety findings are reported for SARMs?

No regulator has approved them for human use. SARMs can build muscle but carry liver, cardiovascular, and hormone-suppression risks, are frequently mislabeled on the gray market, and are banned in sport. They score poorly on safety here despite real anabolic effects.

What cardiovascular findings are reported for TRT?

For men with genuine hypogonadism, the TRAVERSE trial (2023) found no increase in major cardiac events versus placebo, which was reassuring. Supraphysiological or non-prescribed use is a different, higher-risk situation and is illegal without a prescription.

Scores reflect the published evidence, not a recommendation to use any compound or protocol. Nothing here is medical advice. How we score →

← All categories